Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Fig. 3

Changes of cardiac function classification among the subjects after 16 weeks of treatment. “Conspicuous” refers to level 2 improvement in cardiac function. “Valid”refers to level 1 improvement in cardiac function. “Invalid”refers to no improvement or aggravation of cardiac function. P refers to the difference between two groups after treatment

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X